Teligent announced the launch of Cefotan (cefotetan for injection) for the treatment of susceptible lower respiratory tract or urinary tract, skin and skin structure, bone and joint, gynecologic, intra-abdominal infections; and for use in surgical prophylaxis.

Cefotan was initially discontinued by AstraZeneca in 2014; this approval by the Food and Drug Administration (FDA) will help address the shortage in treatment.

RELATED: Cefotan Inj Regains Approval After Discontinuation

The bactericidal action of Cefotan results from cell wall synthesis inhibition. Cefotan has in vitro activity against a range of aerobic and anaerobic gram-positive and gram-negative organisms.  It possesses a high degree of stability in the presence of beta-lactamases including both penicillinases and cephalosporinase of gram-negative bacteria.

Cefotan is available as 1g and 2g strength vials in 10-count trays. It is intended for intravenous or intramuscular administration.

For more information call (856) 697-4397 or visit